LDOS or DT: Which Is the Better Value Stock Right Now?

Zacks Equity Research identifies Leidos (LDOS) as a more compelling value investment than Dynatrace (DT) within the IT Services sector. LDOS holds a #2 (Buy) Zacks Rank, indicating a stronger earnings outlook, and exhibits superior valuation metrics, including a forward P/E of 16.67, PEG ratio of 1.78, and P/B ratio of 5.1. These factors contribute to LDOS receiving a 'B' Value grade, compared to DT's 'D' grade and higher valuation multiples, positioning LDOS as the preferred option for value-focused investors.

Analysis

Based on a comparative value analysis within the IT Services sector, Leidos (LDOS) presents a more compelling investment case than Dynatrace (DT). LDOS holds a Zacks Rank of #2 (Buy), indicating positive revisions to its earnings estimates and an improving earnings outlook. In contrast, DT is rated as a #3 (Hold). The valuation disparity is significant; LDOS trades at a forward P/E ratio of 16.67, substantially lower than DT's 30.32. Furthermore, its PEG ratio of 1.78 is more attractive than DT's 2.37, suggesting a more reasonable price relative to its expected earnings growth. The P/B ratio also favors Leidos at 5.1 versus 5.44 for Dynatrace. These quantitative factors result in LDOS earning a 'B' grade for Value, while DT scores a 'D', reinforcing the conclusion that Leidos is the more undervalued stock of the two based on this specific analytical framework.

Key Decisions for Investors

• Value-focused investors should consider Leidos (LDOS) as a potential long position, given its combination of a positive earnings revision trend and multiple favorable valuation metrics relative to its peer.
• Investors holding or evaluating Dynatrace (DT) for a value portfolio should exercise caution due to its high forward P/E and PEG ratios, which suggest its current price may already reflect future growth expectations.
• The primary driver for this bullish thesis on LDOS is its superior standing in the Zacks Rank and Value Score systems; therefore, any negative revisions to its earnings estimates or a deterioration in its valuation multiples would warrant a reassessment of the position.